Table 2.
Effects of pradigastat on fasting and postprandial triglyceride and apolipoprotein B48Data presented are geometric means (CV %), unless otherwise specified
| Baseline * | Treatment period 1 | Treatment period 2 | Treatment period 3 | ||||
|---|---|---|---|---|---|---|---|
| Pradigastat 20 mg (n = 6) | Pradigastat 40 mg (n = 6) | Pradigastat 10 mg (n = 4) | |||||
| EOT † | Ratio ‡ | EOT † | Ratio ‡ | EOT † | Ratio ‡ | ||
| Fasting TG, mmol/L | 19.21 (35.2) | 12.80. (25.0) | 0.67. (33.1) | 13.97. (79.2) | 0.73. (47.7) | 32.14. (35.8) | 1.41. (26.9) |
| Peak PPTG, mmol/L | 20.91. (27.0) | 12.91. (29.4) | 0.62. (27.8) | 14.38. (84.9) | 0.69. (71.8) | 41.22. (34.1)§ | 1.69. (37.3)§ |
| AUC0–9 PPTG, h*mmol/L | 163.49. (29.3) | 103.16. (22.7) | 0.63. (25.1) | 114.69. (79.7) | 0.70. (65.8) | 321.68. (36.5)§ | 1.63. (37.9)§ |
| Fasting ApoB48, g/L | 0.071. (51.3) | 0.063. (41.6) | 0.88. (25.5) | 0.043. (67.1) | 0.61. (37.0) | 0.113. (47.5) | 1.29. (23.2) |
| Peak PP ApoB48, g/L | 0.079. (34.1) | 0.067. (39.7) | 0.84. (23.8) | 0.048. (56.8) | 0.61. (28.6) | 0.149. (29.7)§ | 1.53. (20.0)§ |
| AUC0–9 PP ApoB48, h*g/L | 0.632. (36.2) | 0.527. (39.9) | 0.83. (22.1) | 0.378. (63.1) | 0.60. (33.3) | 1.261. (30.7)§ | 1.60. (16.2)§ |
ApoB48 = apolipoprotein B48; AUC0–9 = area under curve over 0 to 9 hours; CV = coefficient of variation; EOT = end of treatment; PP = postprandial; TG = triglycerides.
*Baseline values are at Day −1 for all the parameters, except for fasting TG and ApoB48 (mean of Day −1 and Day 1); †EOT values are at Day 21 for all parameters, except for fasting TG and ApoB48 (mean of Day 21 and Day 22); ‡Geometric mean ratio to baseline; §n = 3.